Microglia suppress the secondary progression of autoimmune encephalomyelitis
Abstract
Secondary progressive multiple sclerosis (SPMS) is an autoimmune disease of the central nervous system (CNS) characterized by progressive motor dysfunction, sensory deficits, and visual problems. The pathological mechanism of SPMS remains poorly understood. In this study, we investigated the role of microglia, immune cells in the CNS, in a secondary progressive form of experimental autoimmune encephalomyelitis (EAE), the mouse model of SPMS. We induced EAE in nonobese diabetic mice and treated the EAE mice with PLX3397, an antagonist of colony stimulating factor‐1 receptor, during secondary progression in order to deplete microglia. The results showed that PLX3397 treatment significantly exacerbated secondary progression of EAE and increased mortality rates. Additionally, histological analysis showed that PLX3397 treatment significantly promoted inflammation, demyelination, and axonal degeneration. Moreover, the number of CD4+ T cells in the spinal cord of EAE mice was expanded due to PLX3397‐mediated proliferation. These results suggest that microglia suppressed secondary progression of EAE by inhibiting the proliferation of CD4+ T cells in the CNS.Keywords
Funding Information
- Japan Agency for Medical Research and Development
This publication has 32 references indexed in Scilit:
- NADPH oxidase expression in active multiple sclerosis lesions in relation to oxidative tissue damage and mitochondrial injuryBrain, 2012
- Fibrinogen-induced perivascular microglial clustering is required for the development of axonal damage in neuroinflammationNature Communications, 2012
- Inflammatory Cortical Demyelination in Early Multiple SclerosisNew England Journal of Medicine, 2011
- Animal Models of MS Reveal Multiple Roles of Microglia in Disease PathogenesisNeurology Research International, 2011
- Initiation and Progression of Axonopathy in Experimental Autoimmune EncephalomyelitisJournal of Neuroscience, 2009
- CCR2+Ly-6Chi monocytes are crucial for the effector phase of autoimmunity in the central nervous systemBrain, 2009
- Reversal of axonal loss and disability in a mouse model of progressive multiple sclerosisJournal of Clinical Investigation, 2008
- Secondary progressive multiple sclerosis: current knowledge and future challengesThe Lancet Neurology, 2006
- Immunopathology of secondary‐progressive multiple sclerosisAnnals of Neurology, 2001
- A myelin oligodendrocyte glycoprotein peptide induces typical chronic experimental autoimmune encephalomyelitis in H‐2b mice: Fine specificity and T cell receptor Vβ expression of encephalitogenic T cellsEuropean Journal of Immunology, 1995